🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareMy 18-month semaglutide journey — 6 month update

My 18-month semaglutide journey — 6 month update

DerekSJ_a1c Tue, Jul 9, 2024 at 12:52 PM 39 replies 2,429 viewsPage 1 of 8
This thread is more than 23 months old. Information may be outdated. Consider searching for more recent discussions.
DerekSJ_a1c
Member
378
1,678
Aug 2024
San Jose, CA
Jul 9, 2024 at 12:52 PM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

What I am after is what the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
20 23adam_van, Dr.SurgeonPGH, rachel_ABQ and 17 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Jul 9, 2024 at 1:23 PM#2
DerekSJ_a1c said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

21 24kim_atl_prep, sarah_TO, wendy_avl and 18 others
Reply Quote Save Share Report
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Jul 9, 2024 at 1:54 PM#3
DerekSJ_a1c said:
Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

22 0DeniseRN_TPA, SandraNC_45, Dr.EndoIndy and 19 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Jul 9, 2024 at 2:25 PM#4

This one has a reasonably settled answer, so here it is. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

23 1NurseLeah_Nash, gary_naperville, sean_dublin and 20 others
Reply Quote Save Share Report
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Jul 9, 2024 at 5:16 PM#5
Dr.SleepRoch said:
All true, with one condition: that curve is for people who reached the dose on schedule.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

24 2JenPlateau, SallyK_inj, CryptoCarl and 21 others
Reply Quote Save Share Report
1238

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register